Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Todos Medical Ltd TOMDF

Todos Medical Ltd is a Israel-based clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer. The Companys Total Biochemical Infrared Analysis (TBIA) platform, represents a method for cancer screening of solid tumors using peripheral blood spectroscopy analysis. The process involves observing the immune system’s response to tumor... see more

Recent & Breaking News (GREY:TOMDF)

Todos Medical Announces Insolvency Proceedings in Israel

GlobeNewswire December 22, 2023

Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic

GlobeNewswire September 26, 2023

Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid(TM) and Tollovir(TM) Ingredients

GlobeNewswire August 30, 2023

Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics

GlobeNewswire March 28, 2023

Todos Medical Begins Trading on the OTC Pink Marketplace

GlobeNewswire March 27, 2023

Todos Medical Supports Long COVID Awareness Day

GlobeNewswire March 15, 2023

Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders

GlobeNewswire March 13, 2023

Todos Medical Provides Corporate Update

GlobeNewswire February 23, 2023

Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics

GlobeNewswire February 14, 2023

Todos Medical to Present at the RHK 2022 Disruptive Growth Conference

GlobeNewswire December 6, 2022

Todos Medical's 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022

GlobeNewswire November 29, 2022

Todos Medical to Attend World Antiviral Congress

GlobeNewswire November 22, 2022

Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network

GlobeNewswire November 16, 2022

Todos Medical Announces Third Quarter 2022 Financial Results

GlobeNewswire November 15, 2022

Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022

GlobeNewswire November 14, 2022

Todos Medical Terminates Tollovid(TM) Products License & Distribution Agreement with T-Cell Protect Hellas S.A.

GlobeNewswire November 10, 2022

Todos Medical Announces BioFuture(TM) NYC 2022 Presentation

GlobeNewswire November 4, 2022

Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA

GlobeNewswire October 14, 2022

Todos Medical Provides Corporate Update

GlobeNewswire October 11, 2022

Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics

GlobeNewswire October 6, 2022